Is It Possible to Withdraw Biologics From Therapy in Rheumatoid Arthritis?
Introduction
Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by inflammation and joint destruction that causes significant morbidity and mortality. To prevent joint damage, disease-modifying antirheumatic drugs (DMARDs) such as methotrexate (MTX) should often be started after patients are diagnosed. However, the use of MTX monotherapy often fails to control disease activity and to prevent structural damage, and more effective treatment strategies are thus needed. TNF plays a pivotal role in the pathologic processes of RA through the accumulation of inflammatory cells and the self-perpetuation of inflammation, which leads to joint destruction. The combination of MTX and biologic agents targeting tumor necrosis factor (TNF) has revolutionized the treatment of RA, producing significant improvements in clinical, radiographic, and functional outcomes that were not previously observe. The combination has produced the emerging outcome and upcoming end point for the treatment as the followings.1, 2, 3, 4, 5 Clinical remission is perceived as an appropriate and realistic primary goal in many patients, and its maintenance leads to structural and functional remission.
The possibility of discontinuation of biologic agent treatment after achievement of remission or low disease activity must be considered because of the long-term safety issues found by inhibiting a particular cytokine and the economic burden associated with expensive biological products. The decision to discontinue synthetic DMARDs should be made with caution; such discontinuation results in twice as many flare-ups, difficulties in reintroducing remission, and a halt in damage.6 However, similar studies are not available for the biologic agents it remains unclear whether treatment strategies with biologics targeting induction and/or maintenance of clinical remission can potentially lead to subsequent discontinuation of the TNF inhibitors. The goal of the present article was to determine if discontinuation of biologic agents targeting TNF is possible in RA patients, after obtaining low disease activity or clinical remission during certain periods of use with TNF inhibitors. The content is based on results of a systemic literature review as well as new information.
Section snippets
Methods
A search of PubMed was conducted by using a search strategy that combined terms for rheumatoid arthritis, biological agent, and discontinuation, discontinuing, or cessation. The systematic literature search strategy was as follows: #1, arthritis, rheumatoid [MeSH]; #2, biological agents OR biologics OR TNF inhibitor OR infliximab OR etanercet OR golimumab OR abatacept OR tocilizumab OR certolizumab pegol; #3, clinical trial [Filter]; #4, English [Filter]; #5, discontinuation OR discontinuing OR
Can We Discontinue Infliximab?
Infliximab is an anti-TNF chimeric monoclonal antibody that was approved for the treatment of RA in 1999 in the United States and the European Union. The study regarding biologic-free treatment in RA patients was first reported by a British group as a TNF20 study.9, 14 Patients with early RA who had <12 months of symptoms were treated with a combination of infliximab and MTX. Patients who initiated treatment with infliximab and MTX achieved higher American College of Rheumatology 50% and 70%
Conclusions
After the sustained remission by biologic agents targeting TNF in MTX-naive RA patients and RA patients with inadequate response to MTX, discontinuation of biologic agents is emerging from the risk/benefit point of view, including safety and economical issues. After discontinuing TNF inhibitors, patients with RA could successfully remain in low disease activity or remission without radiologic and functional damage progression of articular destruction. Such a discontinuation of TNF inhibitors is
Conflicts of Interest
Dr. Tanaka has received consulting fees, speaking fees, and/or honoraria from Mitsubishi-Tanabe Pharma, Eisai, Chugai Pharma, Abbott Japan, Astellas Pharma, Daiichi-Sankyo, Abbvie, Janssen Pharma, Pfizer, Takeda Pharma, AstraZeneca, Eli Lilly Japan, GlaxoSmithKline, Quintiles, Merck Sharp & Dohme Corp, and Asahi-Kasei Pharma and has received research grants from Bristol-Myers Squibb, Mitsubishi-Tanabe Pharma, Abbvie, Merck Sharp & Dohme Corp, Chugai Pharma, Astellas Pharma, and Daiichi-Sankyo.
Acknowledgments
This work was supported in part by Research on Rare and Intractable Diseases and Research Grant-In-Aid for Scientific Research by the Ministry of Health, Labor and Welfare of Japan, the Ministry of Education, Culture, Sports, Science and Technology of Japan, and the University of Occupational and Environmental Health, Japan and UOEH Grant for Advanced Research.
The authors thank all medical staff in all institutions for providing the study data.
References (27)
- et al.
Rheumatoid arthritis
Lancet
(2010) - et al.
Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomized controlled trial
Lancet
(2013) - et al.
Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor
Clin Immunol
(2009) - et al.
Differences in binding and effector functions between classes of TNF antagonists
Cytokine
(2009) - et al.
The pathogenesis of rheumatoid arthritis
N Engl J Med
(2011) - et al.
Inflammatory bone loss: pathogenesis and therapeutic intervention
Nat Rev Drug Discovery
(2012) Intensive treatment and treatment holiday of TNF-inhibitors in rheumatoid arthritis
Curr Opin Rheumatol
(2012)Next stage of RA treatment: TNF-inhibitor-free remission will be a possible treatment goal?
Ann Rheum Dis
(2013)- et al.
Treating rheumatoid arthritis to target: recommendations of an international task force
Ann Rheum Dis
(2010) - et al.
Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study
Ann Rheum Dis
(2011)
Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study
Ann Rheum Dis
Benefits 8 years after a remission induction regimen with an infliximab and methotrexate combination in early rheumatoid arthritis
Rheumatology (Oxford)
Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis, RRR (Remission Induction by Remicade in RA) study
Ann Rheum Dis
Cited by (21)
Persistence of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: An analysis of the South Korean National Health Insurance Database
2018, Seminars in Arthritis and RheumatismCitation Excerpt :We could not be sure that discontinuation of the current biologic DMARDs, including switching, restarting, and stopping is only attributable to lack of efficacy or adverse event because the reason of discontinuation was not identified in the claims data. Biologic DMARDs might be discontinued because low disease activity or remission has been achieved, which seems to contradict the interpretation of persistence in terms of effectiveness [25,26]. A further limitation of this study is that the Korean National Health Insurance database provides administrative claims data, which do not contain clinical information as disease activity, and reasons of discontinuation of prior treatment at the time of receiving the index biologic DMARDs.
Combination screening of synthetic drugs and plant derived natural products-Potential and challenges for drug development
2014, SynergyCitation Excerpt :In RA the combination of methotrexate (MTX) with a TNF-α-antagonist was shown to be more effective compared to the single applications [9,14]. Through combinations of Biologicals with MTX for the first time “drug free remissions periods” in RA patients have been achieved, the so called “drug holidays” [15,16]. The great potential of combination therapies can also be assessed from the results obtained by a multimodal treatment – the Bonn-Malmö-Protocol – for another autoimmune disease, the acquired hemophilia (AH).
Discontinuation of biologic DMARDs in a real-world population of patients with rheumatoid arthritis in remission: outcome and risk factors
2022, Rheumatology (United Kingdom)A combination model to predict relapse and successful conventional DMARDs de-escalation in rheumatoid arthritis patients with sustained clinical remission
2019, Clinical and Experimental RheumatologyDiscontinuation of non-anti-TNF drugs for rheumatoid arthritis in interventional versus observational studies: a systematic review and meta-analysis
2018, European Journal of Clinical PharmacologyEvaluation of efficacy of infliximab for retinal vasculitis and extraocular symptoms in Behçet disease
2018, Japanese Journal of Ophthalmology